Label-free multiphoton excitation imaging as a promising diagnostic tool for breast cancer.

artificial intelligence breast cancer multiphoton excitation microscopy rapid diagnosis surgical margin

Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Aug 2022
Historique:
revised: 09 05 2022
received: 10 12 2021
accepted: 11 05 2022
pubmed: 18 5 2022
medline: 10 8 2022
entrez: 17 5 2022
Statut: ppublish

Résumé

Histopathological diagnosis is the ultimate method of attaining the final diagnosis; however, the observation range is limited to the two-dimensional plane, and it requires thin slicing of the tissue, which limits diagnostic information. To seek solutions for these problems, we proposed a novel imaging-based histopathological examination. We used the multiphoton excitation microscopy (MPM) technique to establish a method for visualizing unfixed/unstained human breast tissues. Under near-infrared ray excitation, fresh human breast tissues emitted fluorescent signals with three major peaks, which enabled visualizing the breast tissue morphology without any fixation or dye staining. Our study using human breast tissue samples from 32 patients indicated that experienced pathologists can estimate normal or cancerous lesions using only these MPM images with a kappa coefficient of 1.0. Moreover, we developed an image classification algorithm with artificial intelligence that enabled us to automatically define cancer cells in small areas with a high sensitivity of ≥0.942. Taken together, label-free MPM imaging is a promising method for the real-time automatic diagnosis of breast cancer.

Identifiants

pubmed: 35579268
doi: 10.1111/cas.15428
pmc: PMC9357641
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2916-2925

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP18he0902001
Organisme : Japan Society for the Promotion of Science
ID : JP19H05657
Organisme : Japan Society for the Promotion of Science
ID : JP20K16192
Organisme : Kanae Foundation for the Promotion of Medical Science
Organisme : Kanzawa Medical Research Foundation
Organisme : Osaka Medical Research Foundation for Intractable Diseases
Organisme : Senri Life Science Foundation
Organisme : Takeda Science Foundation

Informations de copyright

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Clin Breast Cancer. 2018 Dec;18(6):e1247-e1250
pubmed: 30241967
Ann Surg Oncol. 2014 Dec;21(13):4202-10
pubmed: 25047464
J Clin Invest. 2013 Feb;123(2):866-73
pubmed: 23321670
Ann Surg. 2017 Feb;265(2):300-310
pubmed: 27429028
Cancer Sci. 2022 Aug;113(8):2916-2925
pubmed: 35579268
J Exp Med. 2021 May 3;218(5):
pubmed: 33666647
Sci Rep. 2017 Jul 31;7(1):6959
pubmed: 28761050
Nat Commun. 2018 Jan 19;9(1):300
pubmed: 29352112
Sci Rep. 2017 Aug 24;7(1):9269
pubmed: 28839164
Nature. 2008 Feb 7;451(7179):720-4
pubmed: 18256671
Diagn Cytopathol. 2021 Apr;49(4):475-479
pubmed: 33405395
J Biophotonics. 2021 Jan;14(1):e202000280
pubmed: 32951321
Int J Cancer. 2021 Aug 1;149(3):635-645
pubmed: 33739453
Cancer Res. 2020 Sep 1;80(17):3745-3754
pubmed: 32718995
J Biomed Opt. 2018 Mar;23(3):1-8
pubmed: 29500874
Arch Pathol Lab Med. 2015 Jun;139(6):796-804
pubmed: 26030249
Nat Protoc. 2012 Mar 08;7(4):654-69
pubmed: 22402635
J Intern Med. 2020 Jul;288(1):62-81
pubmed: 32128929
Breast Cancer Res. 2018 Jul 9;20(1):69
pubmed: 29986750
Nat Commun. 2018 May 29;9(1):2125
pubmed: 29844371
Am J Pathol. 2019 Sep;189(9):1686-1698
pubmed: 31199919
Jpn J Clin Oncol. 2010 Jun;40(6):513-20
pubmed: 20189973
Adv Sci (Weinh). 2019 Feb 25;6(8):1801735
pubmed: 31016109
JAMA Surg. 2019 Feb 1;154(2):126-132
pubmed: 30422226
Br J Ophthalmol. 2019 Feb;103(2):167-175
pubmed: 30361278

Auteurs

Takahiro Matsui (T)

Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan.

Akio Iwasa (A)

Yokohama Plant, Nikon Corporation, Yokohama, Japan.

Masafumi Mimura (M)

Yokohama Plant, Nikon Corporation, Yokohama, Japan.

Seiji Taniguchi (S)

Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan.

Takao Sudo (T)

Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka, Japan.

Yutaka Uchida (Y)

Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Laboratory of Bioimaging and Drug Discovery, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

Junichi Kikuta (J)

Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Laboratory of Bioimaging and Drug Discovery, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

Hidetomo Morizono (H)

Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Breast Surgical Oncology, New Tokyo Hospital, Chiba, Japan.

Rie Horii (R)

Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Pathology, Saitama Cancer Center, Saitama, Japan.

Yuichi Motoyama (Y)

Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

Eiichi Morii (E)

Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan.

Shinji Ohno (S)

Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Yasujiro Kiyota (Y)

Yokohama Plant, Nikon Corporation, Yokohama, Japan.

Masaru Ishii (M)

Department of Immunology and Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan.
WPI-Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Laboratory of Bioimaging and Drug Discovery, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH